REFERENCES
[1] National health commission. 2019 China health statistics yearbook. Beijing, China Union Medical College Press (2019). p. 128.
[2] Joret-Descout, P., Prot-Labarthe, S., Brion, F., Bataille, J., Hartmann, J. F., Bourdon, O. (2015). Off-label and unlicensed utilisation of medicines in a French paediatric hospital. Int. J. Clin. Pharm.  37(6), 1222-1227.
[3] Knopf, H., Wolf, I. K., Sarganas, G., Zhuang, W., Rascher, W., Neubert, A. (2013). Off-label medicine use in children and adolescents: results of a population-based study in Germany. BMC public health , 13(1), 631.
[4] Corny, J., Bailey, B., Lebel, D., Bussières, J. F. (2016). Unlicensed and off-label drug use in paediatrics in a mother-child tertiary care hospital. Paed. Child. Healt.  21(2), 83-87.
[5] Slažneva, J., Kovács, L., Kuželová, M. (2012). Off-label drug use among hospitalized children: identifying extent and nature. Eur. Pharm. J.  59(1), 48-54.
[6] Eguale, T., Buckeridge, D. L., Verma, A., Winslade, N. E., Benedetti, A., Hanley, J. A., et al. (2016). Association of off-label drug use and adverse drug events in an adult population. JAMA Inter. Med.  176(1), 55-63.
[7] Pratico, A. D., Longo, L., Mansueto, S., Gozzo, L., Barberi, I., Tiralongo, V., et al. (2018). Off-label use of drugs and adverse drug reactions in pediatric units: a prospective, multicenter study. Current drug safety  13(3), 200-207.
[8] Wu, W., Tang, Z., Chen, J., Gao, Y. (2019). Pediatric drug development in China: Reforms and challenges. Pharmacol. Res.104412.
[9] General office of the national health commission. General office of the ministry of industry and information technology, general department of the state administration of food and drug administration. (2019). http://www.gov.cn/zhengce/zhengceku/2019-11/18/content_5453049.htm. [Accessed March 30, 2020].
[10] Tsukamoto, K., Carroll, K. A., Onishi, T., Matsumaru, N., Brasseur, D., Nakamura, H. (2016). Improvement of pediatric drug development: regulatory and practical frameworks. Clin. Ther.  38(3), 574-581.
[11] China food and drug administration. China food and drug administration circular on guidelines for publishing real-world evidence to support drug development and review (trial) (no. 1, 2020) (2020). http://www.nmpa.gov.cn/WS04/CL2138/373175.html. [Accessed March 30, 2020].
[12] Preis, M., Breitkreutz, J. (2017). Pediatric drug development and dosage form design. AAPS PharmSciTech  18, 239–240.
[13] Klingmann, V. (2017). Acceptability of mini-tablets in young children: Results from three prospective cross-over studies. AAPS PharmSciTech  18(2), 263-266.
[14] Yen, E., Davis, J. M., Milne, C. P. (2019). Impact of regulatory incentive programs on the future of pediatric drug development. Ther. Innov. Regul. Sci.  53(5), 609-614.
[15] Ward, R. M., Benjamin, D. K., Davis, J. M., Gorman, R. L., Kauffman, R., Kearns, G. L., et al. (2018). The need for pediatric drug development. J. Pediatr.  192, 13-21.
[16] Green, D. J., Zineh, I., Burckart, G. J. (2018). Pediatric drug development: outlook for science‐based innovation. Clin. Pharmacol. Ther.  103(3), 376-378.